BELLUS Health Inc. (BLU)
| Market Cap | 824.09M |
| Revenue (ttm) | 9,524 |
| Net Income (ttm) | -55.42M |
| Shares Out | 106.75M |
| EPS (ttm) | -0.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 667,712 |
| Open | 7.98 |
| Previous Close | 8.07 |
| Day's Range | 7.62 - 8.02 |
| 52-Week Range | 2.60 - 9.84 |
| Beta | -0.50 |
| Analysts | Buy |
| Price Target | 12.85 (+66.5%) |
| Earnings Date | May 9, 2022 |
About BLU
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Financial Performance
In 2021, BELLUS Health's revenue was 16,000, an increase of 6.67% compared to the previous year's 15,000. Losses were -71.22 million, 124.3% more than in 2020.
Financial numbers in millions CADFinancial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BLU stock is "Buy." The 12-month stock price forecast is 12.85, which is an increase of 66.45% from the latest price.
News
Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Wall Street Analysts Believe Bellus (BLU) Could Rally 32%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive t...
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 Inter...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
Here is how Bellus Health (BLU) and Innoviva (INVA) have performed compared to their sector so far this year.
Can Bellus (BLU) Climb 70% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 70.5% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive t...
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Can Bellus (BLU) Climb 88% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at an 87.5% upside potential for Bellus (BLU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev...
Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates
Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
All You Need to Know About Bellus (BLU) Rating Upgrade to Buy
Bellus (BLU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 65% Upside in Bellus (BLU): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive tre...
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering ...
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the ...
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its s...
Here's Why Bellus Health Is Jumping Higher Today
A phase 2 trial with the company's chronic-cough candidate hit its primary endpoint.
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. The post BLU Stock Alert: The Study Data That Has BELLUS Health Blasting H...
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
Bellus Health (BLU) Reports Q3 Loss
Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appe...